Open AccessTrends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease
Author(s) -
Mohamed Noureldin,
Shirley CohenMekelburg,
Asadullah Mahmood,
Ryan W. Stidham,
Peter Higgins,
Shail M. Govani,
Amar R. Deshpande,
Akbar K. Waljee
Publication year - 2020
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izaa127
Subject(s) - medical prescription , medicine , inflammatory bowel disease , sulfasalazine , ulcerative colitis , health plan , retrospective cohort study , disease , residence , logistic regression , pediatrics , health care , demography , pharmacology , sociology , economics , economic growth
5-aminosalicylate (5-ASA) medications have a long history of use for the treatment of inflammatory bowel disease and continue to be widely prescribed today. The effectiveness of 5-ASAs in ulcerative colitis is clear; however, studies have shown little benefit for induction or maintenance treatment of Crohn disease (CD). We aimed to quantify usage and examine trends in 5-ASA prescription rates in patients with CD.